Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC

Abstract excerpt

The FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical trials of selective tyrosine kinase inhibitors (TKI) are underway. Treatment with a single TKI represents a logical step toward personalized cancer therapy, but intrinsic and acquired resistance mechanisms limit their long-term benefit. In this study, we deployed RNAi-based functional genomic screens to identify protein...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Fibroblast Growth Factor Research
• Share to Lung Cancer Treatments and Mutations
• Share to PI3K/AKT/mTOR signaling in cancer